New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
05:48 EDTNVSNovartis announces start of new secukinumab versus Stelara Phase III study
Novartis announced that a new phase IIIb head-to-head study of IL-17A inhibitor secukinumab versus Stelara in moderate-to-severe plaque psoriasis has started patient enrollment.
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
10:32 EDTNVSElbit Imaging announces Gamida Cell enters into agreement with Novartis
Subscribe for More Information
October 11, 2015
13:56 EDTNVSNovartis reports Phase 3 data on Cosentyx for psoriasis
Novartis announced new data demonstrating that Cosentyx, or secukinumab, provides "high" levels of skin clearance and "sustained efficacy" in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years, according to the company. The Phase 3 Cosentyx extension study enrolled 320 patients who received treatment in a fixed dosing schedule for three years. The study showed 69% of patients achieved clear or almost clear skin at year one, which was "extremely well maintained" after three years with 64% of patients continuing to have a PASI 90 response. In addition, 43% of patients maintained completely clear skin at year three, from 44% at year one. Eighty-three percent achieved the standard treatment goal of PASI 75 skin clearance at three years. Cosentyx had a favorable safety profile consistent with that observed in previous Phase 3 studies, Novartis said.
October 8, 2015
05:27 EDTNVSNovartis reports long-term efficacy of Gilenya
Subscribe for More Information
October 7, 2015
16:50 EDTNVSNovartis' Sandoz Canada launches PrSandoz Solifenacin on Canadian market
Sandoz Canada announced the launch of a new drug on the Canadian market, PrSandoz Solifenacin, which is used in reducing urinary urgency, frequency and incontinence. PrSandoz Solifenacin is a generic equivalent to the product Vesikur marketed in Canada under the name PrVesicare. This generic drug is available immediately on the Canadian market. Sandoz Canada is part of Sandoz International GmbH, the world's second largest producer of generic drugs and a company of the Swiss multinational corporation, Novartis (NVS).
07:34 EDTNVSAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
07:23 EDTNVSEuropean Committee Treatment & Research in Multiple Sclerosis holds meeting
Subscribe for More Information
October 6, 2015
13:32 EDTNVSBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
October 5, 2015
05:25 EDTNVSAlcon receives FDA approval for AcrySof IQ Aspheric IOL
Subscribe for More Information
October 1, 2015
11:06 EDTNVSXOMA price target raised to $1.50 from $1 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for XOMA (XOMA) to $1.50 after the company partnered a preclinical TGF-beta antibody with Novartis (NVS) for $37M upfront and up to $480M in milestones. The payment brings XOMA's pro forma cash to $88M, enabling the company to advance its endocrine antibody pipeline, including lead candidate XOMA 358 for hyperinsulinism disorders, Tenthoff tells investors in a research note. The analyst keeps a Neutral rating on the name. The stock is up 20c to 95c in early trading.
07:37 EDTNVSXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information
September 30, 2015
17:04 EDTNVSNovartis says results of Phase 3 study of secukinumab met endpoints
Subscribe for More Information
September 29, 2015
12:35 EDTNVSPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
08:46 EDTNVSNoven reports final decisions in IPRs challenging Novartis' Exelon patch patents
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use